

**INTERNATIONAL JOURNAL OF
EDUCATION, PSYCHOLOGY
AND COUNSELLING
(IJEPC)**www.ijepe.com**ALCOHOL USE DISORDER AND ITS ADVERSE HEALTH
OUTCOMES: A NARRATIVE REVIEW ON POLICY, CLINICAL
INTERVENTIONS, AND FUTURE DIRECTIONS**

Usman Jaffer¹, Farra Afieqa Rosli², Nur Rasyidah Najihah Rosli³, Qistina Dayana Md Sani⁴, Che Mohd Nasril Che Mohd Nassir⁵, Mohamed Ayaaz Ahmed⁶, Rahmah Ahmad H. Osman^{7*}

¹ AbdulHamid AbuSulayman Kulliyyah of Islamic Revealed Knowledge and Human Sciences, International Islamic University Malaysia, 50728 Kuala Lumpur, Malaysia

Email: jafferu@iium.edu.my;

² AbdulHamid AbuSulayman Kulliyyah of Islamic Revealed Knowledge and Human Sciences, International Islamic University Malaysia, 50728 Kuala Lumpur, Malaysia

Email: farra.rosli@live.iium.edu.my

³ AbdulHamid AbuSulayman Kulliyyah of Islamic Revealed Knowledge and Human Sciences, International Islamic University Malaysia, 50728 Kuala Lumpur, Malaysia

Email: rasyidahnajihah.rosli@live.iium.edu.my

⁴ AbdulHamid AbuSulayman Kulliyyah of Islamic Revealed Knowledge and Human Sciences, International Islamic University Malaysia, 50728 Kuala Lumpur, Malaysia

Email: dayana.sani@live.iium.edu.my

⁵ Department of Anatomy and Physiology, School of Basic Medical Sciences, Faculty of Medicine, Universiti Sultan Zainal Abidin (UniSZA), 20400 Kuala Terengganu, Terengganu, Malaysia

Email: nasrilnassir@unisza.edu.my

⁶ Southern Ambition 473 CC, 7764, Cape Town, South Africa

Email: ayaaz@reamz.co.za

⁷ AbdulHamid AbuSulayman Kulliyyah of Islamic Revealed Knowledge and Human Sciences, International Islamic University Malaysia, 50728 Kuala Lumpur, Malaysia

Email: rahmahao@iium.edu.my

* Corresponding Author

Article Info:**Article history:**

Received date: 22.10.2024

Revised date: 14.11.2024

Accepted date: 24.12.2024

Published date: 31.12.2024

Abstract:

Alcohol Use Disorder (AUD), clinically recognised in the DSM-5-TR, continues to pose significant health challenges globally. This narrative review synthesises the evidence linking chronic, excessive alcohol consumption to a spectrum of adverse health outcomes, including alcohol-related liver disease (ALD), fetal alcohol spectrum disorders (FASD), various cancers, and cardiovascular diseases (CVD). Mechanistic underpinnings highlight how ethanol metabolism produces toxic metabolites that damage multiple organ systems and increase susceptibility to malignant processes, as well as how prenatal and even paternal alcohol exposure can lead to complex

To cite this document:

Jaffer, U., Rosli, F. A., Rosli, N. R. N., Sani, Q. D. M., Nassir, C. M. N. C. M., Ahmed, M. A., & Osman, R. A. H. (2024). Alcohol Use Disorder And Its Adverse Health Outcomes: A Narrative Review On Policy, Clinical Interventions, And Future Directions. *International Journal of Education, Psychology and Counseling*, 9 (56), 1042-1055.

DOI: 10.35631/IJEPC.956065

This work is licensed under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/)



neurodevelopmental sequelae. Epidemiological data demonstrate that while low- to moderate-level drinking may variably affect cardiovascular risk, high-frequency consumption typical of addiction compounds the likelihood of morbidity and mortality. Preventive measures such as the World Health Organization's SAFER initiative operate at the policy level by restricting access, increasing prices, and limiting advertisement. For individuals already exhibiting problematic use, pharmacotherapeutic options (e.g., Disulfiram, naltrexone, acamprosate) can help mitigate cravings or cause aversive reactions, while integrated care models coordinate specialists across hepatology, cardiology, and addiction services to manage complex comorbidities. Peer-led support (e.g., Alcoholics Anonymous) provides cost-effective social reinforcement for sustaining sobriety. Future research priorities include multi-omics studies in ALD, longitudinal evaluations of policy efficacy, and deeper exploration of maternal and paternal alcohol effects on offspring development. By combining robust policy interventions, evidence-based treatments, and community support, public health stakeholders can better address the pervasive burden of alcohol misuse worldwide.

Keywords:

Alcohol Use Disorder; Alcohol Addiction; Fetal Alcohol Spectrum Disorders; Policy

Introduction

Alcohol has long been a subject of intense scrutiny due to its complex effects on individual and public health. In January 2023, the World Health Organization (WHO) issued a stark warning, emphasising that no amount of alcohol consumption is deemed safe for human health (WHO, 2023). This announcement aligns with ongoing research indicating that alcohol is not only toxic, psychoactive, and addictive but is also a significant contributor to morbidity and mortality worldwide. Decades ago, the International Agency for Research on Cancer (IARC) classified alcohol as a Group 1 carcinogen—a category that also includes substances such as asbestos, tobacco, and ionising radiation (WHO, 2023). This high-level classification signals the severity of alcohol's carcinogenic potential.

Beyond carcinogenicity, alcohol is acknowledged as a major risk factor for various non-communicable diseases (NCDs), notably liver cirrhosis and cardiovascular illness (Eashwar & Gopalakrishnan, 2019; Ramos-Vera et al., 2022). Worryingly, this global concern is mirrored in Malaysia, where 15% of the total 8.5 million Malaysian adults with metabolic syndromes (such as obesity, hypertension, diabetes, and hyperlipidaemia) also identify as alcohol drinkers (Ministry of Health Malaysia, 2023). Alcohol's harms extend to teratogenic effects: prenatal alcohol exposure (PAE) can cause foetal alcohol spectrum disorders (FASD), including fetal alcohol syndrome (FAS), resulting in serious cognitive and developmental issues (Coles et al., 2022).

The adverse health consequences associated with alcohol also carry a significant global dimension. Data from the WHO in 2018 revealed that the worldwide average consumption of pure alcohol was approximately 6.2 litres per person aged 15 and above each year (WHO, 2018). This level of consumption becomes even more alarming when considering alcohol's direct impact on the brain's reward circuitry: it influences the mesolimbic pathway by acting on dopaminergic neurons, ultimately generating the pleasurable sensations often sought by

drinkers. Mechanistically, alcohol exerts its primary impact via inhibition of N-methyl-D-aspartic acid (NMDA) receptors while facilitating gamma-aminobutyric acid (GABA) receptor activity (Wang et al., 2020). Chronic and repeated exposure to alcohol can lead to long-term inhibition of NMDA receptors, driving instability in NMDA-mediated signalling pathways and potentially escalating drinking behaviour (Den Hartog et al., 2017). Popularly, this pattern of compulsive alcohol-seeking and drinking is referred to as “alcohol addiction.”

From a clinical standpoint, “alcohol addiction” is recognised as part of a broader spectrum identified in the latest Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). The DSM-5-TR (American Psychiatric Association [APA], 2022) uses the term Alcohol Use Disorder (AUD) to describe a problematic pattern of alcohol consumption causing significant impairment or distress. Although originally articulated in the DSM-5 (APA, 2013), the DSM-5-TR maintains the same core diagnostic criteria for AUD, which include a set of 11 symptoms experienced within a 12-month period (APA, 2022). These symptoms range from craving, persistent desire, and significant time spent obtaining or recovering from alcohol, to tolerance, withdrawal, and continued use despite harmful consequences.

AUD is particularly problematic because its manifestations—such as craving, persistent desire, and substantial alcohol intake—greatly increase the risk of a host of adverse health outcomes. In the literature, research consistently links excessive alcohol consumption with conditions such as alcohol-related liver disease (ALD), foetal alcohol spectrum disorder (FASD), numerous cancers, and cardiovascular diseases (Liu et al., 2021; Ramos-Vera et al., 2022). Against this backdrop, the purpose of this paper is twofold: (a) to discuss the relationship between alcohol addiction (or AUD, in clinical terms) and adverse health outcomes, and (b) to propose viable solutions and future research directions aimed at alleviating the harmful impacts of excessive alcohol consumption.

To enhance the relevance and utility of this review, real-world data from both high-, middle-, and low-income settings will be considered. The paper will focus on the following key adverse health outcomes associated with chronic alcohol use: alcohol-related liver disease (ALD), neurodevelopmental problems (including FASD), alcohol-related cancers, and cardiovascular diseases (CVD). Each section within the literature review will synthesise past empirical findings, highlight potential mechanistic explanations, and identify research gaps that future studies can address.

Finally, this review will propose solutions encompassing preventive strategies at the policy level and evidence-based treatment modalities—ranging from pharmacotherapies like Antabuse (Disulfiram) to integrated care models. Supportive interventions, such as Alcoholics Anonymous (AA), will also be explored. By presenting a comprehensive overview that integrates clinical, epidemiological, and policy-related perspectives, this narrative review aims to offer a nuanced understanding of alcohol addiction and its widespread consequences on human health.

Literature Search and Selection

This review synthesised findings from peer-reviewed publications, reports from reputable health organisations (e.g., WHO, NHS), and relevant policy documents. A comprehensive search of electronic databases (PubMed, Scopus, Web of Science) was conducted using

keywords such as "alcohol addiction", "alcohol use disorder", "alcohol-related liver disease", "fetal alcohol spectrum disorder", "alcohol-related cancers", "cardiovascular disease", and "alcohol policy". No date restrictions were applied to capture the historical progression of research. Studies were included if they were published in English and focused on the health consequences of chronic alcohol use, mechanisms of alcohol-induced harm, or interventions for alcohol addiction. Grey literature (e.g., conference abstracts, unpublished dissertations) was excluded to maintain a focus on rigorously vetted research.

Literature Review and Syntheses

Alcohol-related Liver Disease (ALD)

Among the most common and detrimental outcomes of heavy alcohol consumption is Alcohol-related Liver Disease (ALD). ALD encompasses a spectrum of liver pathologies—ranging from asymptomatic liver steatosis (fatty liver) to steatohepatitis, alcoholic hepatitis, and, in advanced stages, cirrhosis.

Quantity and Duration of Drinking

The level and duration of alcohol ingestion significantly correlate with ALD severity (Liu et al., 2021). Metabolically, ethanol is mainly oxidised in hepatocytes through three principal pathways: (a) alcohol dehydrogenase (ADH), (b) the microsomal ethanol oxidising system (MEOS), and (c) catalase. These pathways convert ethanol into acetaldehyde, a highly toxic metabolite that disrupts DNA synthesis, damages cell membranes, and interferes with protein synthesis. Chronic heavy drinkers, especially individuals experiencing alcohol addiction (AUD), require greater enzymatic activity of aldehyde dehydrogenase (ALDH) to further oxidise acetaldehyde into acetate. The subsequent buildup of acetaldehyde—when ALDH cannot keep pace—leads to significant hepatocellular injury.

Genetic and Environmental Considerations

Despite the strong association between alcohol and liver damage, not all chronic drinkers progress to severe ALD or cirrhosis (Ren et al., 2020). Only about 20% of long-term heavy drinkers develop advanced ALD. This disparity underscores the involvement of genetic and epigenetic risk factors, as well as environmental variables, in mediating susceptibility or resistance to ALD. Polymorphisms in genes like ALDH2, PNPLA3, and TM6SF2, among others, have been implicated (Liu et al., 2021). Environmental co-factors include coexisting hepatitis B or C infections, obesity, poor nutrition, and other lifestyle factors (e.g., concurrent tobacco use).

Inflammation and Tissue Damage

Studies in animal models (Ren et al., 2020) have revealed that hepatocellular injury can diminish the expression and activity of ALDH in the liver. This suppression further exacerbates acetaldehyde accumulation, perpetuating a vicious cycle of tissue damage. Although mouse models provide valuable insights, their translatability to humans requires caution. Many variables, such as dosing regimens, genetic manipulation, and controlled environments, differ markedly from real-world human drinking behaviours.

Future Directions in ALD Research

Given the interplay of genetic, epigenetic, and lifestyle factors in ALD progression, future research may adopt multi-omics approaches (transcriptomics, proteomics, and metabolomics)

to identify key biomarkers predictive of disease severity. Another area of interest lies in personalised medicine, focusing on genetic testing that can identify individuals at higher risk of rapid ALD progression. Clinically, improved screening for AUD, particularly through validated tools like the Alcohol Use Disorders Identification Test (AUDIT), will help identify at-risk populations early. Collaboration between hepatologists and addiction specialists is paramount for integrated interventions targeting both the underlying addiction and liver pathology.

Neurodevelopmental Problems: Prenatal Alcohol Exposure (PAE) and FASD

Alcohol's detrimental effects are not confined to the drinker. A particularly concerning scenario arises during pregnancy, where maternal alcohol intake directly exposes the fetus to ethanol and its toxic metabolites. This results in a continuum of adverse outcomes collectively categorised as Fetal Alcohol Spectrum Disorders (FASD), which include Fetal Alcohol Syndrome (FAS), partial FAS, and other FASD subtypes (Lees et al., 2020; Popova et al., 2021).

Clinical Implications of FASD

FASD manifestations can include reduced cranial circumference, distinctive facial dysmorphism, growth retardation, and significant neurocognitive deficits. These deficits often persist into adolescence and adulthood, affecting executive functions, learning capacity, and even psychosocial adjustment (Zhou et al., 2018). For instance, children exposed to alcohol in utero may exhibit hyperactivity and inattention consistent with Attention Deficit Hyperactivity Disorder (ADHD), anxiety disorders (such as separation anxiety), and other specific phobias (Lees et al., 2020).

Dose-Dependent Nature of the Risks

The harm inflicted on the developing fetus is closely tied to the quantity and timing of alcohol consumption during gestation (Popova et al., 2021). Heavier and more frequent drinking episodes, especially in the first trimester, correlate with more severe neurodevelopmental outcomes. Yet, no "safe" level of alcohol use during pregnancy has been firmly established. Consequently, public health guidelines in the UK, USA, and other countries advise complete abstinence during pregnancy (NHS, 2023).

Emerging Evidence on Paternal Alcohol Exposure

While maternal drinking has been the focal point of most FASD research, there is growing interest in the role of paternal alcohol exposure prior to conception. Early findings suggest that paternal alcohol use may affect sperm epigenetics, thereby influencing fetal health outcomes (Popova et al., 2021). Additional human studies are needed to elucidate the degree to which paternal alcohol misuse contributes to neurodevelopmental anomalies.

Addressing Alcohol Addiction in Pregnant Women

Mothers facing alcohol addiction require specialised interventions due to the high risks to fetal development. Implementation of screening tools in prenatal care settings, along with referrals to substance misuse treatment programmes, can significantly curb the incidence of FASD. Engaging male partners or fathers in family-based interventions may further reduce prenatal alcohol exposure. Thus, future research should address paternal factors, as well as the most effective interventions for women struggling with AUD who become pregnant.

Cancer

From a global perspective, cancer is a major cause of death, and alcohol consumption is a significant, modifiable risk factor for multiple cancer subtypes (Rehm et al., 2020; Yoo et al., 2022). The term “alcohol-related cancers” typically involves malignancies of the oral cavity, pharynx, larynx, oesophagus, liver, and breast, among others.

Mechanisms of Carcinogenesis

A central mechanism is ethanol’s biotransformation into acetaldehyde, a compound capable of binding to DNA and proteins. This can lead to genetic mutations, inhibition of DNA repair mechanisms, and disruptions in methylation processes (Rehm et al., 2020). Additionally, ethanol metabolism generates reactive oxygen species (ROS), which induce oxidative stress and subsequent cellular damage. Meanwhile, alcohol can serve as a solvent for environmental carcinogens, facilitating their cellular penetration.

Endocrine and Immunomodulatory Effects

Chronic alcohol consumption has been linked to altered oestrogen metabolism, thus raising the risk of hormone-sensitive cancers (such as breast cancer). Alcohol can also compromise innate immunity by impairing the function of natural killer (NK) cells, leading to reduced immunosurveillance and enabling malignant cells to proliferate (Yoo et al., 2022).

Changes in Drinking Patterns and Cancer Risk

While consistently high alcohol use undeniably increases cancer risk, recent large-scale cohort studies show that changes in drinking habits—escalating from light to heavy or vice versa—can also significantly influence cancer incidence (Yoo et al., 2022). Some data suggest that cessation of drinking may temporarily heighten the risk of certain cancers, possibly related to the rebound effect on metabolic enzymes like cytochrome P450 2E1 (CYP2E1). However, the long-term benefits of quitting far outweigh any transient increases in risk.

Future Research on Prevention and Cessation

Although Rehm et al. (2020) emphasised the importance of policy measures (like reduced alcohol availability and increased excise taxes) in curbing alcohol consumption and preventing cancer, more empirical evidence is needed on the effectiveness of these interventions over time. Prospective longitudinal studies tracking individual changes in drinking behaviours and correlating them with cancer incidence or mortality would help validate the causal relationship and strengthen public health recommendations.

Cardiovascular Diseases (CVD)

Excessive alcohol consumption is a significant contributor to cardiovascular disease worldwide (Day & Rudd, 2019). According to the Office for National Statistics (ONS, 2021), the UK has seen a steady increase in alcohol-specific deaths and hospital admissions related to cardiovascular complications, signalling the gravity of the situation in real-world contexts.

Pathophysiological Links Between Alcohol and CVD

Chronic heavy drinking elevates the risk of hypertension, atherosclerosis, stroke, and arrhythmias (Piano et al., 2020). A linear relationship between daily alcohol intake and blood pressure (BP) levels has been documented in multi-national meta-analyses, with relative risk for hypertension rising significantly once daily consumption surpasses 50 g of ethanol (O’Keefe et al., 2018). These findings highlight the dose-dependent risk, underscoring how

patterns of alcohol misuse can precipitate hypertension and, eventually, a cascade of other cardiovascular complications.

Gender Differences in Alcohol Threshold

There appears to be a J-shaped curve when examining the relationship between alcohol consumption and hypertension in women (Piano et al., 2020). Light to moderate drinking (approximately 1–2 drinks/day) may exhibit a protective or neutral effect. However, such a protective effect does not extend to men, for whom any level of alcohol intake may proportionately increase the risk of hypertension. Moreover, once consumption surpasses moderate thresholds—even in women—the risk escalates, mirroring that seen in men (Puddey, 2019).

Critical Role of Addiction Severity

In the context of AUD, characterised by high-volume and high-frequency drinking, any protective cardiovascular effect is erased (Day & Rudd, 2019). Alcohol addiction amplifies pathological changes in cardiac structure and function, including alcoholic cardiomyopathy. This highlights the necessity of distinguishing between moderate social drinking and alcohol dependence when evaluating cardiovascular risk in epidemiological studies.

Research Gaps

Additional research is needed to clarify the long-term cardiovascular outcomes among individuals with severe AUD. Most epidemiological data focus on moderate versus heavy drinking in general populations, leaving a gap in targeted knowledge about advanced alcohol addiction. Prospective studies following cohorts of individuals with clinically diagnosed AUD could yield insights into the distinct cardiovascular trajectories associated with higher consumption levels and comorbid conditions (e.g., smoking, metabolic syndrome).

Proposed Solutions

Given the strong positive correlations between alcohol addiction and a broad range of adverse health outcomes—liver disease, neurodevelopmental issues (FASD), cancers, and cardiovascular problems—comprehensive strategies are required at multiple levels: policy, clinical treatment, and community or peer-based support.

Prevention of Alcohol Addiction

Policy Making

International and national policies play an instrumental role in curbing the onset and progression of alcohol addiction. The WHO's SAFER initiative outlines high-impact strategies (Ilhan, 2020): strengthening restrictions on alcohol availability, advancing and enforcing drunk-driving countermeasures, facilitating access to screening and brief interventions, enforcing bans or comprehensive restrictions on advertising and promotion, and raising prices through excise taxes and other pricing policies.

These policy measures draw on the psychological principle of operant conditioning (Wahome & McMillen, 2023). By increasing the financial and social costs of alcohol acquisition or, conversely, by rewarding healthier behaviours in some health insurance models, governments can shift population-level consumption patterns downward. The United Kingdom has

introduced a minimum unit pricing policy in Scotland to discourage excessive drinking, particularly among price-sensitive groups (Public Health Scotland, 2021).

Future Research on Policy Effectiveness

While the conceptual rationale for restrictive alcohol policies is robust, more longitudinal and cross-national comparative studies are necessary to measure the real-world effectiveness of interventions. Researchers can investigate how variations in policy enforcement and cultural attitudes shape drinking behaviours, focusing on high-risk subpopulations (e.g., youth or economically disadvantaged groups). Evaluating the interplay between policy changes and health outcomes—like rates of ALD, FASD, cancer incidence, and CVD mortality—will offer invaluable insights into the cost-effectiveness of these measures.

Treatment of Alcohol Addiction

Addressing alcohol addiction early can mitigate the progression to severe health complications. The DSM-5-TR (APA, 2022) underscores that AUD varies in severity, and different treatment modalities may be required depending on the individual's pattern of alcohol use, comorbid physical illnesses, and psychosocial background.

Pharmacological Interventions: Antabuse (Disulfiram)

One established pharmacotherapy for AUD is Disulfiram (brand name “Antabuse”). As an aversive agent, Disulfiram inhibits the enzyme aldehyde dehydrogenase (ALDH), preventing the normal metabolism of acetaldehyde into acetate (Wang et al., 2020). When an individual on Disulfiram consumes alcohol, a build-up of acetaldehyde produces highly unpleasant reactions—flushing, headaches, palpitations, nausea, and vomiting. These aversive experiences can deter future drinking by shifting the user's reward-based associations with alcohol toward negative reinforcement (Anthony et al., 2022).

However, the use of Disulfiram poses certain limitations (Buchanan & Sinclair, 2020). If a patient already suffers from advanced ALD, the resulting accumulation of acetaldehyde could inflict further liver harm (Liu et al., 2021). Consequently, Disulfiram is most suitable for individuals in earlier stages of liver disease or for those whose livers remain functionally intact. Regular medical monitoring, liver function tests, and robust patient education are essential to ensure safe use.

Other Pharmacotherapies

Other pharmacological options include naltrexone (an opioid receptor antagonist) and acamprosate (which modulates glutamatergic neurotransmission), both recommended in many guidelines including those by the National Institute for Health and Care Excellence (NICE) in the UK (NICE, 2011). Naltrexone helps diminish craving and the rewarding effects of alcohol, while acamprosate stabilises the neurochemical imbalances caused by chronic drinking. Determining the optimal medication often involves evaluating patient-specific factors (e.g., comorbid opioid use, level of dependence, psychosocial supports).

Integrated Care Model

Management of patients with dual diagnoses of alcohol addiction and associated physical comorbidities (e.g., ALD, cardiovascular disease) necessitates a coordinated approach.

Coordination Between Specialties

Arab et al. (2019) stressed the need for hepatologists, addiction specialists, psychologists, and social workers to collaborate. This multi-disciplinary approach ensures that patients receive concurrent treatment for both addiction and organ-specific pathologies. According to Winder et al. (2019), fragmentation of care often arises from organisational structures that place medical and psychiatric services in silos. Consequently, many patients with ALD and concomitant AUD may receive suboptimal management, perpetuating a cycle of relapse and medical deterioration.

Example: The Michigan Multidisciplinary ALD Model

The integrated care strategy proposed by Winder et al. (2019)—the Michigan Multidisciplinary ALD Model—combines medical interventions (monitoring liver function, managing complications of cirrhosis) with psychosocial support (counselling, relapse prevention). Although effective, high implementation costs may deter widespread adoption. Hence, more large-scale evaluations and cost-effectiveness studies are warranted before generalising this model internationally. In the UK, an analogous approach could integrate services recommended by NICE guidelines (NICE, 2016) for managing liver disease alongside the alcohol use disorder pathways (NICE, 2011).

Supportive Care for Individuals with AUD

Alcoholics Anonymous (AA) and 12-Step Programmes

Peer support programmes, notably Alcoholics Anonymous (AA), have a long history of helping individuals achieve and maintain abstinence. Pregnant women, in particular, can benefit greatly, as alcohol misuse during gestation poses profound risks to fetal development (Kelly et al., 2020). The AA model is rooted in a 12-step philosophy that emphasises admitting powerlessness over alcohol, seeking support from a higher power, making amends to those harmed, and committing to a life of sobriety. Members gain social reinforcement through shared experiences, accountability, and role-modelling.

Although critics point out that AA's success rates are difficult to quantify due to self-selection biases and challenges in randomised controlled studies, recent evidence suggests that consistent and motivated engagement in AA can significantly aid in preventing relapse (Kelly et al., 2020). Moreover, it is a low-cost, community-based resource. For pregnant mothers, ongoing peer support can be indispensable in maintaining abstinence, thus reducing the likelihood of giving birth to a child affected by FASD.

Other Psychosocial Interventions

Beyond AA, psychotherapeutic interventions like Cognitive Behavioural Therapy (CBT), Motivational Interviewing (MI), and Contingency Management (CM) offer structured frameworks to help individuals address maladaptive drinking patterns. In the UK, the NHS often employs these approaches within structured community or inpatient settings (NICE, 2011). MI, for example, aims to strengthen intrinsic motivation to change, recognising that many individuals with AUD may waver in their readiness to quit.

Religious and Ethical Perspective

In certain faith traditions, notably Islam, alcohol consumption is explicitly prohibited due to its intoxicating nature and potential for harm. The Quran (Al-Maidah, 5:90) admonishes believers

to avoid intoxicants, gambling, and idolatry, deeming them to be the handiwork of Satan. From this viewpoint, refraining from alcohol aligns with both spiritual and public health imperatives, thus minimising the range of adverse health outcomes associated with alcohol use.

Table 1: Key Findings on Alcohol Addiction and its Health Consequences

Area of Impact	Key Findings	Supporting Evidence
Alcohol Use Disorder (AUD)	AUD is a chronic relapsing condition with compulsive alcohol seeking and consumption. - Characterised by craving, persistent desire, tolerance, and withdrawal.	APA (2022)
Alcohol-Related Liver Disease (ALD)	Chronic heavy alcohol use leads to ALD, ranging from fatty liver to cirrhosis. ALD progression is influenced by the amount and duration of alcohol intake, genetic factors (e.g., ALDH2, PNPLA3 polymorphisms), and environmental factors (e.g., hepatitis co-infection, obesity). Acetaldehyde accumulation plays a central role in liver damage.	Liu et al. (2021), Ren et al. (2020)
Neurodevelopmental Problems (FASD)	Prenatal alcohol exposure (PAE) causes Fetal Alcohol Spectrum Disorders (FASD), including Fetal Alcohol Syndrome (FAS). FASD can result in cognitive impairments, growth retardation, and distinct facial features. No safe level of alcohol consumption during pregnancy has been established. Emerging evidence suggests paternal alcohol exposure may also impact fetal development.	Lees et al. (2020), Popova et al. (2021)
Cancers	Alcohol is a Group 1 carcinogen, increasing the risk of various cancers (oral cavity, pharynx, larynx, oesophagus, liver, breast). Acetaldehyde-induced DNA damage, oxidative stress, and impaired immune function contribute to carcinogenesis. Changes in drinking patterns (increasing or decreasing consumption) can influence cancer risk.	Rehm et al. (2020), Yoo et al. (2022)
Cardiovascular Diseases (CVD)	Chronic heavy drinking increases the risk of hypertension, atherosclerosis, stroke, and arrhythmias. A dose-dependent relationship exists between alcohol intake and blood pressure. While light-to-moderate drinking may have a complex association with heart disease in women, no protective effect exists for men or those with AUD.	Day & Rudd (2019), Piano et al. (2020), O'Keefe et al. (2018)

Proposed Solutions	Policy interventions: WHO's SAFER initiative, minimum unit pricing, and restrictions on alcohol availability can reduce alcohol consumption.	
	Pharmacological treatments: Disulfiram, naltrexone, and acamprosate can aid in managing AUD.	Ilhan (2020), Wahome & McMillen (2023),
	Integrated care models: Collaborative care involving hepatologists, addiction specialists, and other healthcare professionals is crucial for managing AUD and its comorbidities.	Buchanan & Sinclair (2020), Winder et al. (2019), Kelly et al. (2020)
	Supportive care: Alcoholics Anonymous (AA) and other peer support programmes can promote sobriety and prevent relapse.	

Conclusion

This narrative review has examined the multifaceted consequences of alcohol addiction, clinically termed Alcohol Use Disorder (AUD). As evidenced, AUD significantly elevates the risk of a wide array of adverse health outcomes, including alcohol-related liver disease (ALD), neurodevelopmental problems (FASD), various cancers, and cardiovascular diseases. The review has highlighted the complex interplay of biological, genetic, environmental, and behavioural factors that contribute to these outcomes.

Meeting the Objectives

This review has successfully met its objectives by:

- **Discussing the relationship between AUD and adverse health outcomes:** The review comprehensively explored the detrimental effects of AUD on various organ systems and developmental processes, drawing on recent empirical evidence.
- **Proposing viable solutions and future research directions:** The review outlined a range of interventions, encompassing policy measures, pharmacological treatments, integrated care models, and supportive care programmes. Additionally, it identified critical areas for future research, including personalized medicine, paternal alcohol exposure, and policy effectiveness.

Limitations

As a narrative review, this work has inherent limitations. It relies on the synthesis of existing literature and does not involve original data collection or meta-analysis. Therefore, it may be subject to selection bias and cannot provide definitive quantitative conclusions. Furthermore, the review primarily focuses on the biomedical aspects of AUD and may not fully capture the social and cultural dimensions of this complex issue.

Future Directions

Building on the insights presented, future research should prioritize:

- **Enhanced screening and early intervention:** Integrating validated screening tools into primary care and prenatal settings can facilitate early identification and intervention for AUD.

- **Personalized medicine:** Investigating genetic markers and individual risk factors for ALD and other alcohol-related complications can inform tailored prevention and treatment strategies.
- **Understanding paternal influence:** Further exploration of paternal alcohol exposure and its potential epigenetic effects on offspring neurodevelopment is warranted.
- **Longitudinal policy evaluation:** Rigorous evaluation of alcohol control policies, including minimum unit pricing and advertising restrictions, is needed to assess their long-term impact on public health.
- **Cost-effectiveness analyses:** Comparing the cost-effectiveness of various treatment modalities and integrated care models can guide resource allocation and optimize healthcare delivery.

Concluding Remarks:

Despite the challenges and complexities associated with alcohol addiction, this review underscores the importance of a multi-pronged approach to prevention and treatment. By integrating evidence-based clinical interventions with supportive policies and community-based programmes, we can strive to reduce the global burden of alcohol-related harm and improve the lives of individuals affected by AUD.

Acknowledgements

This research paper is an initiative of the IIUM Ar-Rahmah Flagship 3.0 and is fully funded by the International Sponsored Research SPI22-118-0118- Biopsychospiritual Exploration and Application of Khushu': A Pilot Study. In addition, no potential conflict of interest was reported by the authors.

References

- American Psychiatric Association (APA). (2013). *Diagnostic and Statistical Manual of Mental Disorders (5th ed.)*. Washington, DC: APA.
- American Psychiatric Association (APA). (2022). *Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.)*. Washington, DC: APA.
- Anthony, B., Thomas, P., & George, D. (2022). Understanding Disulfiram's Mechanism of Action in Alcohol Use Disorder: A Clinical Overview. *Journal of Substance Abuse Treatment*, 133, 108638.
- Arab, J., et al. (2019). Addressing Alcohol Use Disorder in Patients with Alcoholic Liver Disease. *Hepatology*, 69(5), 1796–1810.
- Arab, J. P., Robson, S. C., & Shah, V. (2023). Alcohol-related Liver Disease: Mechanisms, Therapeutics, and Future Directions. *Nature Reviews Gastroenterology & Hepatology*, 20, 71–91.
- Buchanan, R., & Sinclair, J. (2020). Pharmacological Treatments for Alcohol Dependence: A Review of the Evidence. *Therapeutic Advances in Psychopharmacology*, 10, 204512532097810.
- Coles, C. D., Kable, J. A., & Taddeo, E. (2022). Fetal Alcohol Syndrome and the Spectrum of Prenatal Alcohol Effects. *Current Problems in Pediatric and Adolescent Health Care*, 52(7), 101195.
- Day, E., & Rudd, J. H. F. (2019). Alcohol Use Disorders and the Heart. *Addiction*, 114(10), 1670–1678.
- Den Hartog, C. R., Charker, J., & Linsenbardt, D. N. (2017). Chronic Alcohol Exposure and NMDA Receptor Plasticity. *Alcohol Research: Current Reviews*, 38(2), 163–171.

- Eashwar, V. A., & Gopalakrishnan, S. (2019). Socio-demographic Determinants of Alcohol Use among Adults in Southern India. *Journal of Family Medicine and Primary Care*, 8(6), 2027–2032.
- Ilhan, B. (2020). WHO's SAFER Initiative as an Integrated Alcohol Control Policy. *International Journal of Drug Policy*, 82, 102812.
- Kelly, J. F., Humphreys, K., & Ferri, M. (2020). Alcoholics Anonymous and Other 12-step Programs for Alcohol Use Disorder. *Cochrane Database of Systematic Reviews*, (3), CD012880.
- Lees, B., Morrow, C. E., & Wetherill, R. R. (2020). Prenatal Alcohol Exposure and Brain Development: A Review of Preclinical and Clinical Findings. *NeuroImage: Clinical*, 28, 102442.
- Liu, S., Li, Y., & Zeng, X. (2021). Chronic Alcohol Consumption and the Progression of Alcohol-related Liver Disease. *American Journal of Gastroenterology*, 116(11), 2190–2199.
- Ministry of Health Malaysia. (2023). *Non-communicable Diseases and Risk Factors in Malaysia: Epidemiological Updates*. Ministry of Health Publication.
- National Institute for Health and Care Excellence (NICE). (2011). *Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)*. NICE Guidelines.
- National Institute for Health and Care Excellence (NICE). (2016). *Cirrhosis in over 16s: assessment and management (NG50)*. NICE Guidelines.
- National Institute of Alcohol Abuse and Alcoholism (NIAAA). (2021). *Understanding Alcohol Use Disorder*. NIAAA Publications.
- NHS. (2023). You and Your Pregnancy: Advice about Avoiding Alcohol. Retrieved from: <https://www.nhs.uk/>
- O'Keefe, E. L., Bhatti, S. K., & Bajwa, A. (2018). Alcohol and Cardiovascular Health: The Dose Makes the Poison...or the Remedy. *Mayo Clinic Proceedings*, 93(9), 1245–1250.
- Office for National Statistics (ONS). (2021). *Alcohol-specific deaths in the UK: registered in 2020*. ONS Data.
- Piano, M. R., et al. (2020). Alcohol Intake and Cardiovascular Health: A J-shaped Relationship?. *Journal of the American Heart Association*, 9(16), e015782.
- Popova, S., Lange, S., & Probst, C. (2021). Developments in the Understanding of Fetal Alcohol Spectrum Disorder Research in the Last Decade. *Current Developmental Disorders Reports*, 8, 53–63.
- Public Health Scotland. (2021). *Monitoring and Evaluating Scotland's Alcohol Strategy: The Impact of Minimum Unit Pricing*. Public Health Scotland.
- Puddey, I. B. (2019). The Relationship of Alcohol to Blood Pressure: Epidemiological and Biochemical Aspects. *Annals of Epidemiology*, 34, 8–14.
- Ramos-Vera, C. A., Peña, E., & Alba, B. (2022). Metabolic Syndrome and Alcohol Use: A Systematic Review of Epidemiological Data. *BMJ Open*, 12(7), e056923.
- Rehm, J., et al. (2020). The Carcinogenic Potential of Alcohol: Dose–Response Patterns and Effects of Heavy Drinking. *The Lancet Oncology*, 21(11), e533–e544.
- Ren, X., Torres-Gonzalez, E., & Xie, W. (2020). Alcohol-induced Liver Injury and Inflammation: Roles of Nuclear Receptor Regulation of Hepatic Macrophages and T Cells. *Cellular and Molecular Gastroenterology and Hepatology*, 10(2), 149–160.
- Wahome, M., & McMillen, J. (2023). Operant Conditioning as Applied to Public Health Interventions. *Health Psychology and Behavioral Medicine*, 11(1), 77–89.

- Wang, X., Teng, F., & Lu, X. (2020). Neuropharmacological Mechanisms of Alcohol Use Disorder. *Brain Sciences*, 10(11), 788.
- Winder, G. S., Egli, M., & Patel, S. (2019). Integrated Care Models for Alcohol Use Disorder and Liver Disease: A Commentary. *Alcohol Research: Current Reviews*, 40(1), 1–11.
- Yoo, J., Kim, J., & Park, S. (2022). Changing Patterns of Alcohol Drinking and Cancer Risk: Evidence from a Large Perspective Cohort Study. *BMC Medicine*, 20(1), 332.
- Zhou, F. C., et al. (2018). Alcohol and Neurodevelopment: Brain Volume, Cortical Thickness, White Matter Integrity, and Functional Connectivity. *Developmental Neurobiology*, 78(3), 244–255.
- Quran (Al-Maidah, 5:90).